Review and approval process:


Stage 1: Expression of Interest

After submitting your initial expression of interest, a scope assessment is conducted by the Programme Manager to identify projects that meet the scope criteria.

Projects that fit the criteria will be sent to the funding partners for review.

The partners will assess the projects against set criteria, including target novelty, and the strength of the evidence linking the target to the psychiatric disorder of interest.  Applications that are of interest to 3+ Partners, will be invited to attend a meeting with those interested Partners on the 2nd November 2021.

Stage 2: Partner meeting

You will be asked to provide a short (20 min) presentation on your target of interest, and will have the opportunity to discuss your idea with the Partners. During this meeting, the Partners will ask questions and provide feedback.

Stage 3: Full application

You will be invited to submit a full application, which incorporates feedback given during the Partner meeting. A second review stage is then initiated in which the targets of interest are considered for their scientific, legal, intellectual property, and commercial aspects.

Applications that receive two or more expressions of interest from the Consortium Members are progressed for project development in collaboration with one of our Partner CROs. This is an iterative and fully collaborative process between the applicant(s), MDC and Consortium Members, capitalising on their drug discovery and development expertise to generate a robust and detailed experimental and project plan.

It is expected that successful projects will be selected by the end of the year and developed and launched in early 2022.

Find out more

On 24th September 2021, the Psychiatry Consortium will launch its 4th call for proposals. This time, the application and review process has been reimagined to provide more opportunities for applicants to engage with our funding partners, and to receive additional feedback on their applications.

Psychiatry Consortium Programme Manager, Dr Laura Ajram, outlines the new process in further detail in this short webinar.

View webinar